贝达药业：目前，公司上市产品已达八款

Core Viewpoint - The company emphasizes its commitment to innovation and growth, highlighting its increasing revenue and stable dividend policy to benefit investors [1]. Financial Performance - The company has launched eight products since its listing, contributing to revenue growth [1]. - For the period from January to September 2025, the company achieved a revenue of 2.717 billion yuan, representing a year-on-year increase of 15.90% [1]. - The company's EBITDA reached 860 million yuan, reflecting a year-on-year growth of 20.15%, indicating strong development momentum [1]. Investor Relations - In response to investor concerns about stock performance and dividends, the company reiterated its strategy of sharing growth value through a stable cash dividend policy [1].